ʻO ka Myopia (a i ʻole ka ʻike kokoke) i nā keiki he maʻi ʻike nui loa. Ua manaʻo ʻia e piʻi ka nui o ka honua ma kahi o 50% i ka makahiki 2050 me kahi 9.8% o ka poʻe i loaʻa i ka myopia kiʻekiʻe. Inā mālama ʻole ʻia, holo nā keiki me ka myopia kiʻekiʻe i nā pilikia o nā maʻi maka nui e like me ka retinal detachment, myopic maculopathy, glaucoma, cataracts, etc. Hoʻohana maʻamau ʻia nā lens makaʻala hoʻokahi (SVL) hoʻoponopono i ka myopia akā ʻaʻole lohi i kona holomua. ʻO ka hoʻoikaika ʻana i ka mana myopia e pili ana i ka nānā ʻana i hana ʻia i ke ʻano paʻa i ka makahiki 2021, ʻelua mau hoʻolālā lens hou ʻo ia hoʻi. ʻO nā Lens Spectacle me nā Lenslets Aspherical Highly (HAL) a me nā Lens Spectacle me nā Lenslets Aspherical Slightly (SAL), kēlā me kēia me nā aniani āpau i hōʻike ʻole i ka hopena i nā hana ʻike i hoʻāʻo ʻia a ua ʻike ʻia he palekana no ka mālama myopia. Ua hōʻike ʻia nā haʻawina ma hope mai ʻoiai ua hoʻemi ʻo HAL a me SAL i ka nui o ka piʻi ʻana o ka myopia a me ka elongation axial, ʻoi aku ka maikaʻi o ka mana o ka myopia i ka HAL. Eia kekahi, ʻo ka hoʻohana lōʻihi ʻana i nā makaaniani HAL i hōʻemi i ka loaʻa ʻana o ka myopia kiʻekiʻe a hiki ke hoʻopilikia i ka steepness retinal a me ka symmetry. Ma muli o ka loiloi o nā hōʻike, ua hāʻawi ʻo US FDA i ka mana kūʻai aku ma 25 Kepakemapa 2025 iā Essilor Stelest mau maka aniani no nā keiki 6 a 12 mau makahiki. Loaʻa ka hāmeʻa i nā "lens nānā me nā lenslets aspherical". He 9 mm ke anawaena akaka o na Lens ma ke kikowaena, i hoopuniia e na apo o na lens li'ili'i (li'ili'i, ho'oki'eki'e kiko) ma ke koena o ka lens. Hāʻawi nā lenslets peripheral i ka defocus māmā āpau, e kōkua i ka hoʻolohi i ka piʻi ʻana o ka myopia. ʻO nā maka aniani ʻo Essilor Stelest ka maka aniani mua i hōʻike ʻia e lohi i ka piʻi ʻana o ka myopia i nā keiki.
Ua loa'a i ka US FDA ka mana kū'ai e ka US FDA ma ka 25 Kepakemapa 2025, i ho'olālā 'ia e ho'oponopono a ho'omalu i ka pi'i 'ana o ka myopia ma nā keiki 6 a hiki i ka 12. Ua ho'okumu 'ia ka 'ae ma ka loiloi 'ana i 'elua makahiki o ka 'ikepili mai kahi ho'okolohua lapa'au i hō'ike 'ia ua ho'olō'ihi 'ia nā lens maka aniani Essilor Stelest i ka holomua o ka myopia. Ua hāʻawi ʻia i ka inoa ʻo Breakthrough Device ma mua ma 30 ʻApelila 2021 e wikiwiki i kona hoʻomohala ʻana a me ka loiloi.
ʻO nā lens eyeglass Essilor Stelest he mau lens hoʻonani me nā "lenslets aspherical". He 9 mm ke anawaena akaka o na Lens ma ke kikowaena, i hoopuniia e na apo o na lens li'ili'i (li'ili'i, ho'oki'eki'e kiko) ma ke koena o ka lens.
Hāʻawi nā lenslets ʻaoʻao i ka defocus māmā āpau, hiki ke kōkua i ka hoʻolohi i ka piʻi ʻana o ka myopia i nā keiki. ʻO kēia ke ʻano o ka lens spectacle Essilor Stelest he hoʻomaikaʻi hou i nā lens concave maʻamau i hoʻohana ʻia e hoʻoponopono i ka myopia.
ʻO Myopia i nā keiki - he mea nui e pili ana i ke olakino lehulehu
ʻO ka Myopia (ʻike ʻia ʻo ka ʻike kokoke a i ʻole ka ʻike pōkole) kahi hiʻohiʻona maʻamau kahi e ʻike maopopo ʻia ai nā mea kokoke, akā ʻike ʻia nā mea mamao. Hoʻopili ʻia nā lens maoli a me nā ʻāpana ʻē aʻe o nā maka i ke ʻano e nānā ai ke kiʻi o nā mea i mua o ka retina ma mua o ka retina. He maʻi ʻike nui loa ia, ʻo ia hoʻi ma waena o ka poʻe ʻōpio 10-25 mau makahiki, i manaʻo ʻia i ke ʻano o kahi hopohopo olakino koʻikoʻi o ka honua. ʻO kekahi mau ʻāina ʻo ʻAsia i hoʻopilikia nui ʻia. Ma Kina, ma kahi o 47% o ka heluna kanaka i loaʻa i ka myopia i ka makahiki 2020. ʻO ka prevalence i nā keiki a me nā ʻōpio he 53.6% a ʻo ka nui o ka prevalence o nā haumāna kulanui ma mua o 90%. ʻIke ʻia ke ʻano like ma nā ʻāina Hikina a me ʻAsia Hema. I ka USA, pili ia ma kahi o 40% o ka heluna kanaka kahi e piʻi wikiwiki ai ka helu prevalence ma waena o nā keiki a me nā ʻōpio. Ma waena o ke keʻokeʻo ʻEulopa holoʻokoʻa prevalence ma kahi o 4.7% me 13.4% ma Norewai, 11.4% ma Kelemānia, a me 19.9% ma Ireland. He haʻahaʻa loa ka laha ma ʻApelika. I ka nānā ʻana i ke ʻano o kēia manawa, ua manaʻo ʻia e piʻi ka nui o ka honua ma kahi o 50% i ka makahiki 2050 me kahi o 9.8% mau kānaka i loaʻa i ka myopia kiʻekiʻe. Inā ʻaʻole mālama ʻia, holo nui ka poʻe me ka myopia kiʻekiʻe i ka pilikia o ka ʻike maka (retinal detachment, myopic maculopathy, glaucoma, a me nā cataracts) ma hope o ke ola. I ka nānā ʻana i ke ʻano o ka maʻi pinepine, ua manaʻo ʻia kahi kumu hoʻohālike piha no ka pale ʻana a me ka mālama ʻana i ka myopia i nā keiki a me nā ʻōpio. ʻO ka hoʻomalu ʻana i ka myopia ma muli o ka spectacle ke ala nui.
ʻO ka hoʻolālā hou o nā lens makaʻala no ka hoʻomalu ʻana i ka myopia
Ua hoʻomaka ka hoʻoikaika ʻana i ka mana myopia e pili ana i ka nānā ʻana me ka paʻi ʻana (i ka makahiki 2021) o nā hopena o ka loiloi ʻana o nā hoʻolālā lens hou ʻelua no kā lākou hopena i nā hana ʻike ma nā pākeke maʻamau. Loaʻa i kēlā me kēia hoʻolālā nā lenslets peripheral. Hoʻohana ʻia kahi lens hihiʻo hoʻokahi (SVL) ma ke ʻano he mana. ʻO nā hoʻolālā ʻelua ʻo ia hoʻi. Ua ʻike ʻia ka palekana o nā Lens Spectacle me ka Highly Aspherical Lenslets (HAL) a me Spectacle Lenses me Slightly Aspherical Lenslets (SAL) no ka hoʻomalu ʻana i ka myopia no ka mea ʻaʻole lākou i hōʻike i ka hopena i nā hana ʻike i hoʻāʻo ʻia.
Ma hope o ka makahiki 2022, ua paʻi ʻia nā hopena o kahi hoʻokolohua lapaʻau ma luna o nā keiki 157 e loiloi i ka maikaʻi o nā lens spectacle me nā lenslets aspherical kiʻekiʻe (HAL) a me nā lenslet aspherical iki (SAL) vis-a-vis kuʻuna ʻike ʻike maka hoʻokahi (SVL) i ka mālama ʻana i ka holomua myopia i 2 mau makahiki. Ua hōʻike ʻia ka haʻawina ʻoiai ʻo ka HAL a me ka SAL i hōʻemi i ka nui o ka piʻi ʻana o ka myopia a me ka elongation axial, ʻoi aku ka maikaʻi o ka asphericity o nā lenslets i ka myopia ʻoi aku ka maikaʻi, ʻo ia hoʻi, pili ka HAL me ka ʻoi aku ka maikaʻi o ka mana myopia efficacy. Hāʻawi kēia i ka hoʻolālā HAL i ke kukui.
ʻO nā Lens Spectacle me nā Highly Aspherical Lenslets (HAL) pale i ka myopia
Ua hōʻike ʻia kahi haʻawina hou 5 makahiki (i paʻi ʻia ma 5 Malaki 2025) ma 43 mau mea komo mai ka hui HAL kumu i hōʻike ʻia ʻo ka hoʻohana ʻana i nā lens aniani me nā lenslets aspherical loa (HAL) i pale i ka like o 3 mau makahiki o ka holomua myopia a me ka lōʻihi axial (AL) elongation maikaʻi. Eia kekahi, ʻo ka hoʻohana lōʻihi ʻana i nā aniani HAL i hōʻemi i ka ulu ʻana o ka myopia kiʻekiʻe. ʻO kekahi noiʻi hou (i paʻi ʻia ma 29 Malaki 2025) i noiʻi i nā hopena o ka HAL ma ka lōʻihi o ka maka peripheral (PEL) a me ka refraction peripheral (PR) i nā keiki i ʻike ʻia ʻo ka hoʻololi ʻana a i ʻole ka hoʻomau ʻana i ka lole HAL hiki ke hoʻolōʻihi i ka lōʻihi o ke kikowaena a me ke kino o ka lōʻihi o ka maka. ʻO ka hoʻohana ʻana i nā lens makaʻala me nā lenslets aspherical kiʻekiʻe (HAL) hiki ke hoʻopilikia i ke koʻikoʻi o ka retinal a me ka symmetry.
Loaʻa iā "Nā Lens Spectacle me nā Lenslet Aspherical" ka ʻae kūʻai aku a FDA
Ma muli o ka loiloi ʻana o ʻelua makahiki o ka ʻikepili mai ka hoʻāʻo ʻana i hōʻike i nā lens eyeglass Essilor Stelest i hoʻolōʻihi i ka holomua o ka myopia (e like me ka hoʻohālikelike ʻia me nā lens hoʻomalu ʻike hoʻokahi), ua hāʻawi ʻo US FDA i ka mana kūʻai aku ma 25 Kepakemapa 2025 i nā lens makaaniani Essilor Stelest i hoʻolālā ʻia e hoʻoponopono a mālama i ka piʻi ʻana o ka myopia i nā keiki 6 a 12 makahiki. ʻO ia ka maka aniani mua i hōʻike ʻia e lohi i ka piʻi ʻana o ka myopia i nā keiki. Ua hāʻawi ʻia i ka inoa "breakthrough device" ma mua o 30 ʻApelila 2021 e wikiwiki i kāna hoʻomohala ʻana a me ka loiloi.
Aia a hiki i kēia manawa, ʻo ka lens pili wale nō ka mea i ʻae ʻia no ka mālama ʻana i ka piʻi ʻana o ka myopia no nā keiki ma ka pūʻulu makahiki 8-12. Ka mea hou i aponoia ʻO Essilor Stelest nā maka aniani hāʻawi i kahi koho no nā keiki ma ka pūʻulu makahiki 6-7. Hāʻawi pū ia i kahi koho haʻahaʻa haʻahaʻa i nā keiki āpau i paʻakikī ke hoʻohana i nā lens pili ma muli o nā hanana ʻino e like me nā maʻi.
***
E hoʻomaopopo ':
- Zhao, L., et al. ʻO ka prevalence a me nā kumu pilikia o ka myopia ma waena o nā keiki a me nā ʻōpio ma Hangzhou. Sci Rep 14, 24615 (2024). DOI: https://doi.org/10.1038/s41598-024-73388-7
- Gao Y., ¶ AL 2021. Ka hopena o nā lens makaʻala no ka mana myopia ma nā hana ʻike. Published: 16 September 2021. DOI: https://doi.org/10.1111/opo.12878
- Bao J., et al.2022. Nā Leni Manaʻo Me nā Lenslet Aspherical no ka Mana Myopia vs Nā Lens Nānā Nānā Hoʻokahi: He Ho'āʻo Hoʻomaʻamaʻa Randomized. JAMA Ophthalmol Paʻi ʻia: 31 Malaki 2022;140;(5):472-478. DOI: https://doi.org/10.1001/jamaophthalmol.2022.0401
- Li, X., et al 2025. Ka mana o ka myopia i ka pono o na lens makamaka me na lenslets aspherical loa: na hopena o kahi a'o hahai 5 makahiki. Maka a me Vis 12, 10 (2025). Hoʻopuka ʻia: 05 Malaki 2025. DOI: https://doi.org/10.1186/s40662-025-00427-3
- Huang Y., et al 2025. Ka hopena o nā lens makamaka me nā lenslets aspherical loa i nā loli o ka lōʻihi o ka maka a me ka asymmetry. Hoʻopuka ʻia: 29 Malaki 2025. DOI: https://doi.org/10.1111/opo.13500
- ʻO ka hoʻāʻo hoʻāʻo - ʻoi aku ka maikaʻi o nā Lens Wear i nā ʻōpio Progressing Myopes (SWAP). Loaʻa ma https://clinicaltrials.gov/study/NCT06520124
- Hoʻopuka Nūhou FDA. Ua ʻae ʻo FDA i ke kūʻai aku ʻana i nā Lenses Makaaniani mua e hoʻolohi i ka holomua o ka Myopia Pediatric. 25 Kepakemapa 2025. Loaʻa ma https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-eyeglass-lenses-slow-progression-pediatric-myopia
- Essilor. E hoʻoponopono i kou ʻike - Stelest. Loaʻa ma https://www.essilor.com/uk-en/products/stellest/
***
***
Pākuʻi pili
- 'Autofocals', he Makaaniani Prototype no ka Ho'oponopono 'ana i ka Presbyopia (Nalo o ka hihio kokoke) (4 Iulai 2019)
- ʻO Bionic Eye: ʻŌlelo hoʻohiki no ka ʻike no nā poʻe maʻi me ka pōʻino o ka retina a me ka optic (15 Pepeluali 2018)
***
 in children is a highly prevalent vision condition. It is estimated that the worldwide prevalence will reach about 50% by the year 2050 with about 9.8% people affected by high myopia. If untreated, children with high myopia run increased risks of serious eye disorders like retinal detachment, myopic maculopathy, glaucoma, cataracts, etc later in life. Traditionally used single-vision spectacle lenses (SVL) correct myopia but do not slow its progression. The efforts towards spectacle-based myopia control took concrete shape when, in 2021, two novel lens designs viz. Spectacle Lenses with Highly Aspherical Lenslets (HAL) and Spectacle Lenses with Slightly Aspherical Lenslets (SAL), each with peripheral lenslets showed no effect on tested visual functions and were found to be safe for myopia control. Subsequent studies showed that while both HAL and SAL reduced the rate of myopia progression and axial elongation, HAL has better myopia control efficacy. Also, long-term use of HAL spectacles reduced the incidence of high myopia and could impact retinal steepness and symmetry. Based on evaluation of evidence, US FDA granted marketing authorisation on 25 September 2025 to Essilor Stellest eyeglass lenses for children 6 to 12 years old. The device comprises of “spectacle lenses with aspherical lenslets”. Lenses have a clear 9 mm diameter area in the centre, which is surrounded by rings of peripheral lenslets (tiny, raised dots) on the rest of the lens. The peripheral lenslets provide peripheral light defocus, which help to slow the progression of myopia. Essilor Stellest eyeglass lenses are the first eyeglass lenses shown to slow progression of myopia in children.){kind=link}